Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

Listing of Claims

Claim 1-12. (Cancelled)

Claim13. (Currently Amended) A compound of formula (I')



(I')

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof wherein

R^1 and R^2 each independently represents hydrogen, C_{1-4}alkyl, NR^9R^{10}, C_{1-4}alkyloxy or Het^3-O-C_{1-4}alkyl; or

R^1 and R^2 taken together with the carbon atom with which they are attached from a C_{3-6}cycloalkyl;

R^4 represents hydrogen, C_{1-4}alkyl, or C_{2-4}alkenyl;

U represents hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxy, phenyl, halo, oxo, carbonyl or hydroxyl;

R^5 and R^6 are each independently selected from hydrogen, C_{1-4}alkyl, C_{1-4}alkyloxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, C_{1-4}alkylcarbonyl, C_{1-4}alkylcarbonyl substituted with one or where possible two or three substituents each independently selected from halo, C_{1-4}alkyl, and C_{1-4}alkyloxy or R^5 and R^6 each independently represent C_{1-4}alkyl substituted with phenyl;

R^7 and R^8 are each independently selected from hydrogen or C_{1-4}alkyl;

R^9 and R^{10} are each independently selected from hydrogen, C_{1-4}alkyl or C_{1-4}alkyloxycarbonyl;

R^{11} and R^{12} are each independently selected from hydrogen, halo, C_{1-4}alkyl, C_{1-4}alkyloxy, hydroxy, nitro, Het^4, phenyl, phenyloxy, C_{1-4}alkyloxycarbonyl, hydroxycarbonyl, NR^5R^6, C_{1-4}alkyloxy substituted with one or where possible two or three substituents each independently selected from hydroxycarbonyl, Het^2 and NR^7R^8, C_{2-4}alkenyl substituted with one substituent selected from phenyl-C_{1-4}alkyl-oxycarbonyl, C_{1-4}alkyloxycarbonyl, hydroxycarbonyl, Het^5-carbonyl, and

C_{1-4}alkyl substituted with one or where possible two or three substituents independently selected from halo, dimethylamine, trimethylamine, amine, cyano, Het^6, Het^7-carbonyl, C_{1-4}alkyloxycarbonyl or hydroxycarbonyl;

Het^1 represents a heterocycle selected from pyridinyl, piperinidyl, pyrimidinyl, pyrazinyl, piperazinyl, pyridazinyl, indolyl, isoindolyl, indolinyl, furanyl, benzofuranyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, benzothiophenyl, thiophenyl, 1,8-naphthyridinyl, 1,6-naphthyridinyl, quinolinyl, isoquinolinyl, 1,2,3,4-tetrahydro-isoquinolinyl, quinoxalinyl, quinazolinyl, phthalazinyl, 2H-benzopyranyl, 3,4-dihydro-2H-benzopyranyl, 2H-benzothiopyranyl, 3,4-dihydro-2H-benzothiopyranyl or 1,3-benzodioxolyl;

Het^2 represents a monocyclic heterocycle selected from piperidinyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, 2H-pyrrolyl, pyrrolyl, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, or morpholinyl, said Het^2 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;

Het^3 represents a monocyclic heterocycle selected from 2H-pyranyl, 4H-pyranyl, furanyl, tetrahydro-2H-pyranyl, pyridinyl, piperidinyl, or furanyl;

Het^4 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl, triazolyl, tetrazolyl or morpholinyl, said Het^4 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;

Het^5 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^5 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy; ~~preferably piperazinyl or morpholinyl~~;

Het^6 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^6 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy;

Het^7 represents a monocyclic heterocycle selected from pyridazinyl, pyrimidinyl, pyrrolidinyl, pyrazinyl, piperazinyl or morpholinyl, said Het^7 optionally being substituted with one or where possible two or more substituents each independently selected from hydroxy, carbonyl, C_{1-4}alkyl or C_{1-4}alkyloxy~~; preferably piperazinyl or morpholinyl; in particular morpholinyl~~.

Claim 14-22. (Cancelled)

Claim 23. (Previously presented) A compound according to claim 13, wherein R^1 and R^2 each independently represents hydrogen, C_{1-4}alkyl, or C_{1-4}alkyloxy.

Claim 24. (Previously presented) A compound according to claim 13, wherein R^1 and R^2 each independently represents methyl or methoxy.

Claim 25. (Withdrawn) A compound according to claim 13, wherein R^1 and R^2 taken together with the carbon atom with which they are attached form cyclopropyl or cyclobutyl.

Claim 26. (Previously presented) A compound according to claim 13, wherein R^4 represents hydrogen.

Claim 27. (Previously presented) A compound according to claim 13, wherein U represents hydrogen, hydroxy or halo.

Claim 28. (Withdrawn) A compound according to claim 13, wherein Het^5 represents a monocyclic heterocycle selected from piperazinyl or morpholinyl;

Claim 29. (Withdrawn) A compound according to claim 13, wherein Het^7 represents a monocyclic heterocycle selected from preferably piperazinyl or morpholinyl.

Claim 30. (Previously presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and, as an active ingredient, an effective 11β-HSD1 inhibitory amount of a compound of claim 13.

Claim 31. (Withdrawn) A process of preparing a pharmaceutical composition a defined in claim 31, wherein a pharmaceutically acceptable carrier is intimately mixed with an effective 11β-HSD1 inhibitory amount of a compound of claim 13.

Claim 32. (Previously presented) A compound according to claim 13, wherein the compound is:

(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-methyl-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-methoxy-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-hydroxy-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3,5-dimethyl-benzeneacetamide);
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-3-(phenylmethoxy)benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-(carboxymethoxy)-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-hydroxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-fluorotricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;
(1α,2β,3β,5β,7β)-N-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;
(1α,2α,3β,5β,7β)-N-(5-methoxytricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-benzeneacetamide;

N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-(carboxymethoxy)-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-[2-(4-morpholinyl)ethoxy]-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3,5-dimethoxy-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-methyl-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-methoxy-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3-hydroxy-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-3,5-dimethyl-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-4-fluoro-benzeneacetamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-1-phenyl-cyclopropanecarboxamide;
N-(tricyclo[3.3.1.13,7]dec-2-yl)-α,α-dimethyl-2,6-difluoro-benzeneacetamide;
3-(3-{2-[(5-fluoro-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoic acid;
4-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)butanoic acid; and
tert-butyl-4-[3-(3-{2-[(5-hydroxy-2-adamantyl)amino]-1,1-dimethyl-2-oxoethyl}-5-methylphenyl)propanoyl]-1,4-diazepane-1-carboxylate; or a N-oxide, a pharmaceutically acceptable addition salt, or a stereochemically isomeric form thereof.